Related references
Note: Only part of the references are listed.The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Andreas Venizelos et al.
ENDOCRINE-RELATED CANCER (2022)
ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study
Laura Gerard et al.
NEUROENDOCRINOLOGY (2021)
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms
Chiara Liverani et al.
ENDOCRINE PATHOLOGY (2021)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix
Adela Cimic et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2021)
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Fiona Blackhall et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies
Camille Tlemsani et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas A Review
Johannes Stelwagen et al.
JAMA ONCOLOGY (2021)
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
Anish Thomas et al.
CANCER CELL (2021)
The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix
Xuan Pei et al.
GYNECOLOGIC ONCOLOGY (2021)
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma et al.
CANCER DISCOVERY (2021)
Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas
Sun Mi Lee et al.
SCIENTIFIC REPORTS (2021)
Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma
Akihiro Ohmoto et al.
MODERN PATHOLOGY (2021)
Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors
Alex Chambers et al.
CURRENT ONCOLOGY REPORTS (2021)
Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes
Renda Li et al.
NATURE COMMUNICATIONS (2021)
Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer
Ayushi S. Patel et al.
SCIENCE ADVANCES (2021)
Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder
Fatao Liu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study
Maria Rodriguez-Remirez et al.
NEUROENDOCRINOLOGY (2020)
Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin
Adele Busico et al.
NEUROENDOCRINOLOGY (2020)
Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
Jaume Capdevila et al.
CLINICAL CANCER RESEARCH (2020)
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas
Constantinos E. Alifieris et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
Hua Zhang et al.
CANCER CELL (2020)
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P. Patel et al.
CLINICAL CANCER RESEARCH (2020)
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
Alexandra N. Corella et al.
CLINICAL CANCER RESEARCH (2020)
Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System
Jiazhang Xing et al.
FRONTIERS IN ONCOLOGY (2020)
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate
Abbie S. Ireland et al.
CANCER CELL (2020)
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model
Vincent Faugeroux et al.
NATURE COMMUNICATIONS (2020)
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Ningni Jiang et al.
MOLECULAR BIOLOGY REPORTS (2020)
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Alvaro Quintanal-Villalonga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer
Susanne Hipp et al.
CLINICAL CANCER RESEARCH (2020)
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
Xin Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
Alberto Puccini et al.
CLINICAL CANCER RESEARCH (2020)
Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma
Luohai Chen et al.
Clinical Colorectal Cancer (2020)
Comparative genomics of high grade neuroendocrine carcinoma of the cervix
R. Tyler Hillman et al.
PLOS ONE (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma
He-Li Gao et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity
Kathryn L. Simpson et al.
NATURE CANCER (2020)
Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers
Mark A. Rubin et al.
MOLECULAR CELL (2020)
An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping
Kenta Kawasaki et al.
CELL (2020)
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis
Alireza Tabibzadeh et al.
SCIENTIFIC REPORTS (2020)
Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers
Yuji Eso et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma
Levent Dizdar et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma
Eliah R. Shamir et al.
MODERN PATHOLOGY (2019)
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia
Florian Boesch et al.
ENDOCRINE-RELATED CANCER (2019)
Immunotherapy for small cell lung cancer: mechanisms of resistance
Gerhard Hamilton et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix
Sarah Morgan et al.
HISTOPATHOLOGY (2019)
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Loredana Puca et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma
Rocio Garcia-Carbonero et al.
ONCOLOGIST (2019)
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
Min-Wei Yang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
PD-L1 Expression and Immune Cell In fi ltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity
Martina Ferrata et al.
FRONTIERS IN ONCOLOGY (2019)
Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies
Nikolas G. Balanis et al.
CANCER CELL (2019)
MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
Milind D. Chalishazar et al.
CLINICAL CANCER RESEARCH (2019)
DLL3: an emerging target in small cell lung cancer
Dwight H. Owen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Bo Liu et al.
CLINICAL CANCER RESEARCH (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target
Vadim S. Koshkin et al.
CLINICAL CANCER RESEARCH (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile
B. C. M. Hermans et al.
LUNG CANCER (2019)
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
Xueqian Gong et al.
CANCER DISCOVERY (2019)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2019)
Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix
Deyin Xing et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
Alice Lallo et al.
CLINICAL CANCER RESEARCH (2018)
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study
Thomas Walter et al.
DIGESTIVE AND LIVER DISEASE (2018)
Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3
Bjoern Konukiewitz et al.
HUMAN PATHOLOGY (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma
Edmund C. P. Chedgy et al.
JOURNAL OF PATHOLOGY (2018)
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer
Kentaro Tanaka et al.
LUNG CANCER (2018)
Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics
Peiye Shen et al.
ONCOGENE (2018)
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm
Giuseppe Pelosi et al.
VIRCHOWS ARCHIV (2018)
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Julie George et al.
NATURE COMMUNICATIONS (2018)
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience
Mohammed Salhab et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon
Jarred Burkart et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
Guido Rindi et al.
MODERN PATHOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition
Deshui Jia et al.
CANCER DISCOVERY (2018)
A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers
Bryan A. Smith et al.
CELL REPORTS (2018)
Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
Jung Wook Park et al.
SCIENCE (2018)
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis
Matthew T. Chang et al.
CLINICAL CANCER RESEARCH (2018)
Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
Saori Mishima et al.
ESMO OPEN (2018)
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Wei Zhang et al.
CLINICAL CANCER RESEARCH (2018)
Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162,983 Cases
Arvind Dasari et al.
CANCER (2018)
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Timothy L. Lochmann et al.
CLINICAL CANCER RESEARCH (2018)
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D
Michele Simbolo et al.
JOURNAL OF PATHOLOGY (2017)
In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components
Christine Woischke et al.
MODERN PATHOLOGY (2017)
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories
Massimo Milione et al.
NEUROENDOCRINOLOGY (2017)
Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti PD-1/PD-L1 therapy
Jordan A. Roberts et al.
HUMAN PATHOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
Lloyd T. Lam et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Biology and evolution of poorly differentiated neuroendocrine tumors
David S. Rickman et al.
NATURE MEDICINE (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification
Aurel Perren et al.
NEUROENDOCRINOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
Sheng Yu Ku et al.
SCIENCE (2017)
MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance
Amy S. Farrell et al.
NATURE COMMUNICATIONS (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Merkel cell carcinoma
Juergen C. Becker et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications
Guenter Kloeppel
VISCERAL MEDICINE (2017)
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
Triparna Sen et al.
CANCER RESEARCH (2017)
Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review
Daniel M. Girardi et al.
CANCER TREATMENT REVIEWS (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Gurkan Mollaoglu et al.
CANCER CELL (2017)
NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas
Lydia Meder et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression
Hideaki Ogiwara et al.
CANCER DISCOVERY (2016)
Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study
Namrata Vijayvergia et al.
BRITISH JOURNAL OF CANCER (2016)
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Etienne Dardenne et al.
CANCER CELL (2016)
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
John K. Lee et al.
CANCER CELL (2016)
Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer
Michael Frumovitz et al.
GYNECOLOGIC ONCOLOGY (2016)
Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival
Dane C. Olevian et al.
HUMAN PATHOLOGY (2016)
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo
Barbara A. Helfrich et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
R. Garcia-Carbonero et al.
NEUROENDOCRINOLOGY (2016)
BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy
Samuel J. Klempner et al.
CANCER DISCOVERY (2016)
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Seung Tae Kim et al.
JOURNAL OF CANCER (2016)
PD-L1 expression in small cell neuroendocrine carcinomas
Anne M. Schultheis et al.
EUROPEAN JOURNAL OF CANCER (2015)
Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor
Nobuyoshi Takizawa et al.
HUMAN PATHOLOGY (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity
Nora Sahnane et al.
ENDOCRINE-RELATED CANCER (2015)
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Camilla L. Christensen et al.
CANCER CELL (2014)
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Hsueh-Li Tan et al.
CLINICAL CANCER RESEARCH (2014)
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Cassandra L. Hodgkinson et al.
NATURE MEDICINE (2014)
Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors
Mohid S. Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications
Jean-Yves Scoazec
NEUROENDOCRINOLOGY (2013)
Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
Juan Miguel Mosquera et al.
NEOPLASIA (2013)
Colorectal Poorly Differentiated Neuroendocrine Carcinomas and Mixed Adenoneuroendocrine Carcinomas: Insights Into the Diagnostic Immunophenotype, Assessment of Methylation Profile, and Search for Prognostic Markers
Stefano La Rosa et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
Shinichi Yachida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
Characterization of the cell of origin for small cell lung cancer
Kwon-Sik Park et al.
CELL CYCLE (2011)
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran et al.
CANCER DISCOVERY (2011)
Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer
M. H. Lawson et al.
BRITISH JOURNAL OF CANCER (2010)
Share Paper
